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Abstract
Background: The relationship between non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis
(AS) is currently debated. Using observational data from the South Swedish Arthritis Treatment Group register, we thus
aimed to compare clinical development and treatment adherence between nr-axSpA and AS patients during three
years of anti-TNF (tumor necrosis factor) therapy in clinical practice, and to explore the impact of inflammatory activity
measured by CRP (C-reactive protein) at treatment initiation.
Methods: Nr-axSpA and AS patients (n = 86/238) in southern Sweden, commencing anti-TNF therapy 1999-2011, were
followed during three years. Anti-TNF cessation was defined as stopping therapy, without restarting another anti-TNF
agent within three months. Differences in the three year developments of patient’s visual analogue scale (VAS) scores
for global health and pain, EuroQol 5-Dimensions utility, evaluator’s global disease activity assessment, CRP, and ESR
(erythrocyte sedimentation rate) were assessed by repeated ANOVA. Anti-TNF adherence was compared by Log rank
test and Cox regression. In a subanalysis, the same outcomes were studied after splitting both groups into patients
with/without baseline CRP elevation.
Results: Nr-axSpA patients were more often female and had lower acute phase reactants at baseline. Apart from CRP,
which remained lower in the nr-axSpA group throughout follow-up (p = 0.004), no between-group differences were
detected regarding clinical developments (p >0.1 for all comparisons) or anti-TNF adherence (hazard ratio: 1.1 (95 % CI
0.7 to 1.8) for the nr-axSpA vs. AS group) during three years. Elevated baseline CRP was similarly associated with
superior clinical outcomes and treatment adherence in both groups.
Conclusions: With the exception of constantly lower CRP levels in the nr-axSpA group, three years anti-TNF therapy
resulted in similar clinical outcomes and treatment adherence in nr-axSpA and AS patients, thus strengthening the
hypothesis that these diagnoses represent different aspects/phases of the same disease.
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Background
Spondyloarthritis (SpA) comprises a range of rheumatic
disorders - ankylosing spondylitis (AS), undifferentiated
SpA, psoriatic arthritis, arthritis related to inflammatory
bowel disease, reactive arthritis, and a juvenile form -
sharing common clinical features, extraarticular manifes-
tations, and a genetic association with the type 1 major
histocompatibility complex HLA-B27. Typical musculo-
skeletal symptoms are divided into peripheral (arthritis,
enthesitis, dactylitis) or axial (sacroiliitis, spondylitis) dis-
ease, of which patients may suffer from either or both.
AS, the classical form of axial SpA, is defined by struc-
tural damage of the sacroiliac joints on conventional ra-
diographs [1]. Many patients, however, display similar
axial symptoms and signs of active sacroiliitis on mag-
netic resonance imaging (MRI) in the absence of such
radiographic changes [2], entailing a risk of delayed or
missed diagnosis. Thus, in 2009, the Assessment of
SpondyloArthritis International Society (ASAS) devel-
oped novel classification criteria for axial SpA, en-
compassing patients both with (AS) and without
radiographic sacroiliitis - the latter phenotype thereby
formally characterized as non-radiographic axial SpA
(nr-axSpA) [3].
Since then a number of studies have compared subjects
with nr-axSpA and AS, finding similar levels of disease ac-
tivity, overall physical impairment, and health-related qual-
ity of life (HRQoL), while the nr-axSpA patients are more
often female, have shorter mean disease duration, and dis-
play lower levels of acute phase reactants and less spinal
immobility [2, 4–10]. The observation that 10–12 % of nr-
axSpA patients progress to develop AS within 2 years,
strengthens the hypothesis that the two entities represent
different aspects/phases of a common pathology [9, 11].
Current treatment guidelines for axial manifestations of
SpA, including both AS and nr-axSpA, recommend the
use of anti-TNF (tumor necrosis factor) agents in cases of
insufficient response or intolerance to non-steroidal anti-
inflammatory drugs (NSAIDs), as conventional disease-
modifying anti-rheumatic drugs (DMARDs) have not been
shown to be effective in this situation [12–14]. The effi-
cacy of anti-TNF treatment in nr-axSpA has been shown
to be similar to that in AS, at least in patients with object-
ive signs of inflammation, such as elevation of C-reactive
protein (CRP) or inflammatory lesions seen on MRI at
baseline [5, 9, 15, 16].
While acknowledging these important previous find-
ings, the overall evidence base concerned with nr-axSpA
remains fairly limited, and results should be confirmed
in further cohorts. Data on long-term efficacy and ad-
herence to anti-TNF therapy in nr-axSpA is also largely
absent. In light of this, we thus applied observational
data from southern Sweden, aiming to compare baseline
characteristics, anti-TNF adherence, and development of
clinical variables during three years of anti-TNF therapy




Since the late 1990s, patients with chronic arthritis
treated with biologic DMARDs in southern Sweden have
been monitored in the observational SSATG (South
Swedish Arthritis Treatment Group) register, involving
12 rheumatology centers [17]. For the present study, bio-
naive patients (≥15 years) with nr-axSpA (n = 86) or AS
(n = 238), commencing anti-TNF treatment between
1999 and 2011, were retrieved from the SSATG register
and compared for baseline characteristics and clinical
development during 3 years of anti-TNF therapy. AS pa-
tients had a clinical diagnosis according to treating rheu-
matologists, which in a previous SSATG validation study
corresponded to at least 90 % fulfillment of the modified
New York criteria (the remaining patients had either in-
complete or missing information in their medical re-
cords, unabling a validation of the AS diagnosis) [1, 18].
The included nr-axSpA patients were all followed at the
central SSATG university clinic in Lund/Malmö, did not
have a clinical diagnosis of psoriatic arthritis, and -
based on data collected on initiation of anti-TNF
therapy - fulfilled the ASAS classification criteria for
axial spondyloarthritis, without having skin psoriasis or
radiographic sacroiliitis on conventional radiographs
(48 and 38 patients, respectively, according to the im-
aging and clinical arms) [3]. In Sweden, anti-TNF
agents were often used to treat patients with this undif-
ferentiated, axial SpA phenotype even before it was for-
mally characterized by ASAS in 2009, explaining the
earlier anti-TNF therapy start dates of some patients
(31 of 86 nr-axSpA patients commencing anti-TNF
therapy prior to 2009).
Treatment
Anti-TNF therapy was started due to high disease activ-
ity and inadequate response or intolerance to one or
more NSAIDs. Treatment decisions were taken by the
responsible rheumatologists, and no formal disease ac-
tivity level was required for initiation of anti-TNF ther-
apy. Indications in both nr-axSpA and AS were,
however, supported by guidelines when they began to
emerge [12, 19], with the non-mandatory Swedish guide-
lines recommending a Bath ankylosing spondylitis dis-
ease activity index (BASDAI) score ≥4 during ≥4 weeks
and previous treatment attempts with ≥2 NSAIDs dur-
ing >3 months in total before starting anti-TNF therapy
in both conditions [14]. Administration intervals and
dosing of etanercept, adalimumab, golimumab, and cer-
tolizumab pegol were in general as recommended by the
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manufacturers. Infliximab was started at 3 mg/kg at
weeks 0, 2, 6, and then every 8 weeks, although in cases
of insufficient response, dose increments were allowed
in steps of 100 mg to a maximum of 500 mg every 4–8
weeks. Facing adverse events, inefficacy, or other causes,
decisions to discontinue anti-TNF therapy altogether or
switch to another agent were left to the responsible
rheumatologists according to clinical practice.
Patients could receive NSAIDs, low dose oral gluco-
corticoids, intra-articular glucocorticoid injections, and
conventional DMARDs both prior to and during the
study period according to clinical practice - the latter
mainly applied in patients with peripheral arthritis.
Follow up and study outcomes
At the start of anti-TNF therapy, demographic data, dis-
ease characteristics (allowing for disease classification as
outlined above), and information on past and present
treatments were reported according to a structured
protocol. [17] Patients were followed for 3 years, with
scheduled visits at baseline, 3, 6, 12, 24, and 36 months
of follow up. At each visit, disease activity was measured
by patient’s visual analog scales (VAS) for global health
and pain (VAS global and VAS pain), evaluator’s global
assessment on a 5-grade Likert scale (Evaluator’s global),
and acute phase reactants (erythrocyte sedimentation
rate (ESR) and CRP), while HRQoL was estimated as
EuroQol 5-Dimensions (EQ-5D) utility, a metric an-
chored at 1 (full health) and 0 (death), applying the
standard British EQ-5D preference set [20, 21]. Use of
the BASDAI and Bath ankylosing spondylitis functional
index (BASFI) were also recommended [22, 23], al-
though not mandatory within the SSATG during the
study period, leading to numbers of missing data values
that were too high for meaningful analysis beyond the
presentation of baseline values.
Thus, the primary outcomes of the present study were
between-group differences (nr-axSpA vs. AS) in the de-
velopments of VAS pain, VAS global, Evaluator’s global,
ESR, CRP, and EQ-5D during 3 years from the start of
anti-TNF treatment. Adherence to anti-TNF therapy was
also compared as a secondary outcome. For this analysis,
switches between anti-TNF therapies occurring within
3 months were allowed and regarded as continuous
treatment, whereas anti-TNF cessation was defined as
discontinuing one treatment course without starting an-
other within 3 months.
Statistics
Baseline characteristics in the nr-axSpA and AS patients
were compared by chi square (χ2) or Fisher’s exact test
for categorical variables and the Mann–Whitney U test
for continuous variables. Whether the two groups dif-
fered in the development of clinical parameters during
3 years of anti-TNF therapy were assessed by repeated
analysis of variance (ANOVA), including all study time
points and adjusting for sex, age, disease duration, pres-
ence of peripheral arthritis (yes/no), and baseline CRP
(the latter excluded from analyses of ESR and CRP de-
velopment). In the main analysis, last observation carried
forward (LOCF) was applied to impute missing data, as
well as from anti-TNF cessation (without restarting anti-
TNF therapy within 3 months) in order to exclude po-
tential effects of later treatments. For EQ-5D, due to a
relatively high proportion of missing data, missing values
at baseline (n(nr-axSpA/AS) = 40/60) and 3 months
(n(nr-axSpA/AS) = 46/81) were first imputed by group-
wise linear regression models with sex, age, disease dur-
ation, peripheral arthritis status (yes/no), VAS global,
VAS pain, evaluator’s global, and health assessment
questionnaire (HAQ) scores at the respective time
points as covariates [24]. Repeated ANOVA restricted to
observed data from patients remaining on anti-TNF
treatment was also conducted for sensitivity analysis.
Adherence to anti-TNF therapy was compared by
Kaplan-Meier curves and the log rank test, and Cox pro-
portional hazards regression, adjusting for age, sex, dis-
ease duration, presence of peripheral arthritis, and
baseline CRP, was also applied to derive a between-
group hazard ratio.
As a sub-analysis, we then split both patient groups into
subjects with (CRP >3.0 mg/l; % (nr-axSpA/AS) = 58/81)
or without CRP elevation at baseline, and compared anti-
TNF adherence and developments of VAS global, VAS
pain, EQ-5D, and evaluatior’s global between the two sub-
groups within each diagnosis. Statistics were as described
above, although limited to analyses of LOCF imputed data
and excluding adjustments for baseline CRP. Finally, anti-
TNF adherence of all four subgroups were compared by
the log rank test.
Ethics, consent and permissions
Ethical approval for the SSATG register study has been
granted by the Regional Ethics Committee at Lund
University, and informed consent was given orally by all
patients before SSATG enrolment. Due to its quality
control character, the SSATG register is part of the legis-
lative documentation demanded in Sweden, and hence




Patients with nr-axSpA were significantly younger and
had a shorter mean disease duration and fewer previous
and ongoing conventional DMARDs than their counter-
parts with AS (Table 1). The male predominance was
also less pronounced in the nr-axSpA group. For disease
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activity all patient-reported outcomes were similar be-
tween the two groups at initiation of anti-TNF therapy,
whereas the more objective measures - evaluator’s glo-
bal, ESR and CRP - were significantly higher among the
AS patients.
Development during anti-TNF therapy
Following anti-TNF initiation, mean values of VAS glo-
bal, VAS pain, EQ-5D utility, Evaluator’s global, ESR,
and CRP improved rapidly in both nr-axSpA and AS pa-
tients, and within 3 to 6 months had reached a plateau,
which was then sustained throughout the 3 years of fol-
low up (Fig. 1 and Additional file 1: Figure S1). By re-
peated ANOVA, regardless of analyzing imputed (Fig. 1)
or observed (Additional file 1: Figure S1) data, no
between-group differences were seen in the 3-year devel-
opments of VAS global, VAS pain, EQ-5D utility, or
Evaluator’s global assessment (p >0.1 for all compari-
sons). Point estimate means of ESR and CRP remained
higher in the AS patients throughout follow up. For
CRP, this between-group difference in the 3-year pattern
was statistically significant when analyzing imputed data
(p = 0.004), while it was only borderline significant in the
observed data analysis (p = 0.06). ESR development did
not differ significantly by either method (p >0.1 for both
analyses).
Adherence to anti-TNF therapy
After three years of follow up, the proportions of pa-
tients with nr-axSpA (n = 60; 70 %) and AS (n = 183;
77 %) remaining on anti-TNF therapy did not differ sig-
nificantly (Fig. 2; log rank test, p = 0.2, Cox proportional
hazard ratio 1.1 (95 % CI 0.7 to 1.8) for the nr-axSpA as
compared to the AS group). Male sex and higher base-
line CRP levels were significantly associated with better
treatment adherence.
Of the 60 nr-axSpA patients adhering to therapy at
3 years, 46 were still receiving their first anti-TNF agent,
11 had switched treatment once, and 3 had switched
treatment twice within 3 months. The corresponding
Table 1 Patient characteristics at initiation of anti-TNF therapy
Baseline characteristics nr-axSpA, n = 86 AS, n = 238 P valuea
Male sex, n (%) 53 (62) 180 (76) 0.013
Age, years 38 (13) 43 (12) <0.001
Disease duration, years 9 (9) 16 (12) <0.001
Peripheral arthritis, n (%) 39 (45) 118 (50) 0.501
VAS global, mm 60 (19) 61 (22) 0.313
VAS pain, mm 60 (22) 62 (22) 0.292
Evaluator’s global, score 0–4 1.7 (0.6) 2.0 (0.7) 0.001
BASDAI score 5.3 (1.7) 5.4 (1.9) 0.727
BASFI score 4.1 (2.3) 4.3 (2.1) 0.503
ESR, mm/h 23 (21) 28 (23) 0.026
CRP, mg/l 10 (13) 23 (26) <0.001
Elevated CRP, n (%)b 47 (58) 177 (81) <0.001
EQ-5D (UK) 0.381
Mean (SD) 0.43 (0.32) 0.45 (0.33)
Median (IQR; range) 0.59 (0.64; –0.22 to 0.80) 0.62 (1.3; –0.48 to 0.80)
Concomitant DMARD (%) 29 (34) 150 (63) <0.001
Previous DMARDs (n) 0.8 (0.9) 1.5 (1.0) <0.001
First anti-TNF agent used, n (%) <0.001c
Infliximab 19 (22) 112 (47)
Etanercept 37 (43) 89 (37)
Adalimumab 20 (23) 37 (16)
Golimumab 7 (8) 0 (0)
Certolizumab pegol 3 (4) 0 (0)
Mean (SD) if not otherwise stated. Missing data in the non-radiographic axial spondyloarthritis (nr-axSpA)/ankylosing spondylitis (AS) groups, n (%) as follows:
Disease duration 1(1)/0(0); visual analog scale (VAS) global 7(8)/24(10); VAS pain 7(8)/24(10); Evaluator’s global 2(2)/18(8); Bath ankylosing spondylitis disease activity
index (BASDAI) 36(42)/105(44); Bath ankylosing spondylitis functional index (BASFI) 35(41)/108(45); erythrocyte sedimentation rate (ESR) 4(5)/19(8); C-reactive protein
(CRP) 5(6)/20(8); EuroQ ol 5-Dimensions (EQ-5D) 40(47)/60(25); Concomitant disease-modifying anti-rheumatic drug (DMARD) 1(1)/1(0.4). aχ2 for categorical and Mann–
Whitney U test for continuous variables. bCRP >3.0 mg/l. cFisher’s exact test
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Fig. 1 Clinical developments during three years of anti-TNF therapy. Mean (95 % CI) developments in visual analog scale (VAS) global, VAS pain, EuroQ
ol 5-Dimensions (EQ-5D) utility, Evaluator’s global assessment of disease activity, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in
the non-radiographic axial spondyloarthritis and ankylosing spondylitis groups over time, using last observation carried forward imputed data
Fig. 2 Adherence to anti-TNF therapy. Kaplan-Meier survival curves from initiation of anti-TNF therapy, showing adherence to anti-TNF treatment
in the non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) groups, respectively. Cessation of anti-TNF therapy was
defined as stopping therapy without restarting another anti-TNF agent within 3 months. Numbers of patients still on anti-TNF treatment at the
respective time points are shown below the graph
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figures in the AS group were 155, 24, and 4 patients, re-
spectively. Of the 26 nr-axSpA and 55 AS patients ceas-
ing anti-TNF therapy prior to 3 years, 6 and 7 patients,
respectively, did so after having switched treatment once
within 3 months, and 2 additional AS patients quit treat-
ment after having switched anti-TNF agents twice.
When only focusing on the first anti-TNF agent used,
the adherence rate over 3 years was better in the AS
group when analyzed by the log rank test (p = 0.04). By
Cox regression analysis, however, no significant
between-group difference was observed (hazard ratio 1.3
(95 % CI 0.9 to 1.9), whereas male sex and higher
Fig. 3 Clinical developments according to C-reactive protein (CRP) status at baseline. Mean (95 % CI) developments in visual analog scale (VAS)
global, VAS pain, EuroQ ol 5-Dimensions (EQ-5D) utility, and Evaluator’s global assessment of disease activity during 3 years of anti-TNF therapy in
patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), who had CRP elevation (CRP >3.0 mg/l) or did
not have CRP elevation (CRP ≤3.0 mg/l) at baseline
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baseline CRP again significantly predicted superior treat-
ment retention.
Baseline CRP sub-analysis
Among both nr-axSpA and AS patients, significantly
larger improvements were seen on repeated ANOVA
in VAS global, VAS pain, and EQ-5D utility scores
among subjects with elevated CRP at baseline (p
<0.05 for all comparisons; Fig. 3). For Evaluator’s glo-
bal assessment, this was also true within the nr-
axSpA group, while it was only borderline significant
among AS patients (p = 0.06).
Likewise, anti-TNF adherence during 3 years of fol-
low up was also significantly superior among both nr-
axSpA and AS patients with increased CRP at base-
line (Fig. 4; nr-axSpA: log rank test, p <0.001; Cox
proportional hazard ratio 0.2 (95 % CI 0.1 to 0.6) for
patients with CRP elevation, as compared to those
without; AS: log rank test, p = 0.006, Cox proportional
hazard ratio 0.5 (0.3 to 0.9)). When comparing all
four subgroups, drug survival did not differ signifi-
cantly between nr-axSpA and AS patients either with,
or without CRP elevation at baseline, whereas the two




In this study, comparing outcomes of anti-TNF ther-
apy in patients with nr-axSpA and AS treated in clin-
ical practice, despite baseline characteristics indicating
more longstanding and objectively more severe dis-
ease in the AS group, no between-group differences
were observed in adherence to anti-TNF therapy, or
in developments of VAS global, VAS pain, EQ-5D
utility, or Evaluator’s global assessment of disease ac-
tivity over 3 years. Mean ESR and CRP levels
remained numerically higher in the AS group
throughout follow up, although only significantly so
for CRP.
Moreover, when splitting patients according to
CRP status at baseline (normal vs. elevated), similar
outcome patterns were again observed in the two
groups, with significantly better treatment adher-
ence and improvements in clinical variables among
both nr-axSpA and AS patients with CRP elevation.
The diversion of anti-TNF adherence curves ob-
served between the overall nr-axSpA and AS groups
(Fig. 2), although non-significant, were thus ex-
plained by the relatively large proportion of nr-
axSpA patients displaying normal CRP at treatment
initiation.
Fig. 4 Adherence to anti-TNF therapy according to C-reactive protein (CRP) status at baseline. Kaplan-Meier survival curves from initiation of anti-TNF
therapy, showing adherence to anti-TNF treatment in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis
(AS) who had CRP elevation (CRP >3.0 mg/l) or did not have CRP elevation (CRP ≤3.0 mg/l) at baseline. Cessation of anti-TNF therapy was
defined as stopping therapy, without restarting another anti-TNF agent within 3 months. Numbers of patients still on anti-TNF treatment at
the respective time points are shown below the graph
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Previous research
The present comparison of baseline characteristics
mainly confirm previous findings, with more female
patients and lower levels of acute phase reactants in
the nr-axSpA group, whereas no differences were seen
in patient-reported disease activity, function, or
HRQoL [2, 4–8, 25]. The observed differences in age
(absent from most prior comparisons) and disease
duration (present in most prior comparisons) should
be interpreted with caution, because this was not an
inception cohort. The larger proportions of patients
with baseline CRP elevation in our study than in
most former studies may be due to varying cutoff
levels and inclusion criteria, but the intergroup rela-
tion remained similar to those previously reported [2,
4–6, 25]. Although the relationship between nr-axSpA
and AS remains fiercely debated, there is some evi-
dence that male sex and CRP elevation may predict
the development of radiographic changes [9]. Accord-
ing to this hypothesis, in particular women with low
levels of inflammation may thus remain in the non-
radiographic stage for many years (perhaps lifelong),
thereby potentially explaining both the baseline differ-
ences seen at the group level and the relatively long
mean disease duration observed in the nr-axSpA co-
horts of this (9 years) and other studies.
The mean baseline BASDAI, BASFI, and VAS global
scores in our cohort are all in the lower ranges of
those reported in randomized controlled trials (RCTs)
of anti-TNF therapy in nr-axSpA and AS [26–32].
Reasons for this are likely to reside in the observa-
tional setting of our study, without strict inclusion
criteria or any mandatory requirement based on dis-
ease activity, to start anti-TNF therapy. The between-
group differences in the first anti-TNF agent used
(Table 1) reflect the earlier approval of this treatment
indication in AS. Although no head-to-head studies
have been performed, there is no evidence to support
a difference in efficacy of the various TNF inhibitors
on manifestations of axial or peripheral SpA [13, 33].
Direct comparisons of the effects of anti-TNF therapy
in patients with nr-axSpA and AS have hitherto been
published from two RCTs and one observational cohort
[5, 15, 16, 25, 34]. In line with the current results, these
studies have demonstrated similar treatment response
rates in both groups, at least in the presence of compar-
able signs of inflammation at baseline, such as elevation
of CRP or inflammatory lesions seen on MRI - both
identified as predictors of anti-TNF response in patients
with nr-axSpA [30–32, 35], and in AS [36–41]. A recent
meta-analysis, assessing all available RCT evidence, also
came to a similar conclusion, with comparable greater
anti-TNF therapy effect sizes over placebo in both diag-
noses when adjusting for publication year as a proxy of
disease severity (as early AS trials enrolled patients with
more longstanding disease) [26]. In terms of effects on
HRQoL, developments in the EQ-5D during anti-TNF
treatment of patients with nr-axSpA and AS have not
been previously compared, although the available 2-
year Short Form 36 and AS quality of life data also
point to comparable HRQoL gains in both groups
[16]. Contrasting with the present results, in the RCT
by Song et al., no difference was observed between
the nr-axSpA and AS groups in development of CRP
[34]. Inclusion in that trial, however, required the
presence of inflammatory lesions seen on MRI, and as
opposed to most other comparisons [2, 5, 7, 25],
mean CRP levels also did not differ at baseline.
Apart from a previous report from our group, find-
ing inflammatory sacroiliitis lesions on MRI to predict
better drug survival of a first TNF inhibitor in nr-
axSpA [42], data on anti-TNF adherence in this diag-
nosis remain sparse. In contrast to our findings, based
on retrospective data, Wallis et al. reported indica-
tions of worse adherence to anti-TNF therapy among
patients with nr-axSpA as compared to AS [7], but
prospectively conducted comparisons are still lacking.
In line with the present results, however, male sex
and CRP elevation at baseline have been shown to
predict better adherence to anti-TNF therapy in pa-
tients with AS [43, 44].
In view of the relatively worse outcomes among both
patient groups without CRP elevation, it may be
hypothezised that in some of these subjects comorbidity
in the form of chronic widespread pain (CWP) was
falsely interpreted as spondyloarthritis activity, thus con-
tributing to the decision to start anti-TNF therapy but
not responding to this treatment. On the contrary, in pa-
tients with more active SpA - as reflected, for example,
by CRP elevation - a certain improvement with anti-
TNF therapy would be expected regardless of the pres-
ence of concomitant CWP or not. While the clinical
arm of the ASAS axial SpA classification criteria has met
with repeated concern that it may falsely classify CWP
patients as having spondyloarthritis [45, 46], in a recent
study presented in abstract form, no patients with pri-
mary fibromyalgia did indeed meet these criteria [47].
On the contrary, however, around 15 % of both AS and
nr-axSpA patients also fulfilled criteria for fibromyalgia,
and other studies have likewise reported a prevalence of
concurrent fibromyalgia in AS at around 10–15 % [48,
49]. Furthermore, patient-reported SpA measures are
known to differentiate poorly between symptoms related
to SpA or CWP [48], with generally worse outcomes
among patients with such comorbidity [49, 50], and
poorer adherence to anti-TNF therapy was also recently
reported in SpA patients with concurrent fibromyalgia
[50].
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Strengths and limitations
The relatively long follow up (3 years) and the opportun-
ity to compare outcomes of anti-TNF therapy in patients
with nr-axSpA and AS treated in clinical practice within
the same observational setting, comprise major strengths
of the present study. To our knowledge, a direct com-
parison of adherence to anti-TNF therapy in patients
with these diagnoses based on prospectively collected
data has been performed here for the first time. Further-
more, the available data on EQ-5D developments during
anti-TNF therapy in patients with nr-axSpA was previ-
ously limited to 1-year results from a single study [30].
In terms of limitations, the open, observational setting
entails inherent risks of bias in patient selection, assign-
ment of treatment, and collection of clinical data. More-
over, the relatively high proportion of missing data for
some outcomes is another frequent problem in observa-
tional studies, and for this reason the results of the main
analysis are presented based on both imputed and ob-
served data. On the other hand, the observational
SSATG setting also implies that patient inclusion will
not be restricted by any predefined level of disease activ-
ity, by rigid treatment guidelines or economical aspects,
but rather will reflect clinical practice. At the same time,
all patients were indeed selected for anti-TNF therapy,
and results are thus not necessarily generalizable to
the nr-axSpA and AS populations at large. The
generalizability in nr-axSpA is also compromised by
the exclusion of patients with a clinical diagnosis of
psoriatic arthritis. For certainty of the diagnoses in
our cohort, high validity for AS diagnoses has previ-
ously been demonstrated within the SSATG register,
while review of the medical records confirmed that all
included nr-axSpA patients fulfilled the ASAS classifi-
cation criteria for axial disease without fulfilling the
modified New York criteria. This said, however, a cer-
tain misclassification between the two diagnoses can-
not be entirely ruled out [51]. Finally, due to their
non-mandatory status within the SSATG during the
study period, the lack of SpA-specific outcome mea-
sures such as BASDAI and BASFI beyond the baseline
values is a main drawback of the present study. Based
on the limited data available, however, developments
in BASDAI closely resembled those of the presented
patient-reported outcomes, whereas this was less ap-
parent for BASFI, although the numbers of observa-
tions were small.
Conclusions
In this comparison of patients with nr-axSpA and AS in
southern Sweden receiving anti-TNF therapy during
3 years in clinical practice, many similarities, and only a
few differences were observed. Patients with nr-axSpA
were more often female and had less elevation of acute
phase reactants at baseline, with CRP levels remaining
significantly lower than in the AS group throughout fol-
low up. In spite of this, patient-reported measures of dis-
ease activity and HRQoL did not differ at baseline and
followed nearly identical trajectories in both groups dur-
ing the 3 years of follow up. Furthermore, no between-
group difference was detected in adherence to anti-TNF
therapy, and CRP elevation at baseline was similarly as-
sociated with superior clinical outcomes and anti-TNF
treatment persistence in both groups. Overall, the
current results thus seem to strengthen the prevailing
hypothesis that nr-axSpA and AS represent different as-
pects/phases of the same underlying disease.
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